Schmitt G, Fürst G, Bamberg M
Bull Cancer. 1986;73(5):577-81.
An analysis of neutron- and neutron-boost irradiation of 191 patients with soft tissue sarcomas is given. 101 patients had T3 (IVA) tumours. The actuarial disease free survival rate of all stages at 6.5 years is 59.8%. Patients with T1 and T2 tumours fared significantly better (73.5%) than patients with T3 tumours (31.3%, p = 0.016). Similar difference are seen according to grade, i.e. 75.1% for G1, 48.3% for G2 (p = 0.035) and 30.9% for G3 tumours (p = 0.024). Patients without microscopic tumour residue fared best (84%), followed by patients with microscopic tumour (72.3%) and patients with gross tumour (29.8%) left behind (p = 0.0003). A functional limb was preserved in 80.5% of patients with extremity lesions (95/118), 50 of them had T3-lesions. The highest local control rate of 76.5% was seen after neutron therapy of differentiated gross tumours. This finding underlines the biological advantage of densely ionizing radiation qualities in these tumours.
对191例软组织肉瘤患者的中子及中子增强照射情况进行了分析。101例患者患有T3（IVA期）肿瘤。所有分期患者在6.5年时的无病生存率为59.8%。T1和T2期肿瘤患者的情况明显好于T3期肿瘤患者（73.5%对31.3%，p = 0.016）。根据分级也可见类似差异，即G1级为75.1%，G2级为48.3%（p = 0.035），G3级肿瘤为30.9%（p = 0.024）。无微小肿瘤残留的患者预后最佳（84%），其次是有微小肿瘤的患者（72.3%）和有肉眼可见肿瘤残留的患者（29.8%）（p = 0.0003）。118例肢体病变患者中有80.5%（95例）保留了功能肢体，其中50例为T3期病变。分化型肉眼可见肿瘤经中子治疗后局部控制率最高，为76.5%。这一发现强调了在这些肿瘤中高电离辐射性质的生物学优势。
